［1］Zhou Z，Hu D.An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China［J］.J Epidemiol，2008，18：209-216.

［2］Chugh SS，Havmoeller R，Narayanan K，et al.Worldwide epidemiology of atrial fibrillation：aglobal burden of disease 2010study［J］.Circulation，2014，129：837-847.

［3］Hu D，Sun Y.Epidemiology，risk factors for stroke，and management of atrial fibrillation in China［J］.J Am Coll Cardiol，2008，52：865-868.

［4］Society of Cardiology，Chinese Medical Association.Retrospective investigation of hospitalized patients with atrial fibrillation in mainland China ［J］.Chin Med J（Engl），2004，117：1763-1767.

［5］Connolly SJ，Ezekowitz MD，Yusuf S，et al.Dabigatran versus warfarin in patients with atrial fibrillation［J］.N Engl J Med，2009，361：1139-1151.

［6］Patel MR，Mahaffey KW，Garg J，et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation［J］.N Engl J Med，2011，365：883-891.

［7］Connolly SJ，Eikelboom J，Joyner C，et al.Apixaban in patients with atrial fibrillation［J］.N Engl J Med，2011，364：806-817.

［8］Giugliano RP，Ruff CT，Braunwald E，et al.Edoxaban versus warfarin in patients with atrial fibrillation［J］.N Engl J Med，2013，369：2093-2104.

［9］Heidbuchel H，Verhamme P，Alings M，et al.European Heart Rhythm Association Practical Guide on the use of new oral safety anticoagulants in patients with non-valvular atrial fibrillation［J］.Europace，2013，15：625-651.

［10］Ruff CT，Giugliano RP，Braunwald E，et al.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation：a meta-analysis of randomised trials［J］.Lancet，2014，383：955-962.

［11］Camm AJ，Lip GY，De Caterina R，et al.2012focused update of the ESC guidelines for the management of atrial fibrillation：An update of the 2010ESC guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association［J］.Eur Heart J，2012，33：2719-2747.

［12］Garcia D，Barrett YC，Ramacciotti E，et al.Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants［J］. Thromb Haemost，2013，11：245-252.

［13］Gage BF，Waterman AD，Shannon W，et al.Validation of clinical classification schemes for predicting stroke：results from the National Registry of Atrial Fibrillation［J］.JAMA，2011，285：2864-2870.

［14］Pisters R，Lane DA，Nieuwlaat R，et al.A novel user-friendly score （HAS-BLED）to assess 1-year risk of major bleeding in patients with atrial fibrillation：the Euro Heart Survey［J］.Chest，2010，138：1093-1100.

［15］Lip GY，Nieuwlaat R，Pisters R，et al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach：the euro heart survey on atrial fibrillation［J］.Chest，2010，137：263-272.

［16］Shurrab M，Morillo CA，Schulman S，et al.Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation：a meta-analysis［J］.Can J Cardiol，2013，29：1203-1210.

［17］Lakkireddy D，Reddy YM，Di Biase L，et al.Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation：results from a multicenter prospective registry［J］.J Am Coll Cardiol，2014，63：982-988

［18］Dans AL，Connolly SJ，Wallentin L，et al.Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized evaluation of long-term anticoagulation therapy（RE-LY）trial［J］.Circulation，2013，127：634-640.

［19］Alexander JH，Lopes RD，Thomas L，et al.Apixaban vs.warfarin with concomitant aspirin in patients with atrial fibrillation：insights from the ARISTOTLE trial［J］.Eur Heart J，2014，35：224-232.

［20］Dewilde WJ，Oirbans T，Verheugt FW，et al.Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention：an open-label，randomised，controlled trial［J］.Lancet，2013，381：1107-1115.

［21］Fox KA，Dabbous OH，Goldberg RJ，et al.Prediction of risk of death and myocardial infraction in the six months after presentation with acute cornonary sysdrome：prospective multinational observational study （GRACE）［J］.BMJ，2006，333：1091.

［22］Subherwal S，Bach RG，Chen AY，et al.Baseline risk of major bleeding in non-ST-segment-elevation myocardoal infraction：the CRUSADE （can Rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA Guidelines）bleeding score［J］.Circulation，2009，119：1873-1882.